drugset / Trial / NCT00830544
Study of Neoadjuvant Chemotherapy of Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the pathological CR rate in breast and lymph nodes of a novel neoadjuvant regimen for invasive breast carcinoma.
Timeline
- Start
- 2008-07
- Primary completion
- 2011-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Capecitabine | Small molecule | 825 mg/m2 | Oral |
| Subject | Cyclophosphamide | Other / unclassified | 500 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | — |
| Subject | Epirubicin | Small molecule | 80 mg/m2 | — |
| Subject | Navelbine | Unknown | 25 mg/m2 | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | — | — |